

"BIPE JUNIOR"



Biologics drug survival in Psoriasis in children under 12 years of age

Newsletter #3 June 4, 2021

We thanks the **Società Italiana di Dermatologia Pediatrica** for its collaboration

	Bipe Jr	Bipe Jr & BiPe
Total number of cases reported Total number of centers Total number of biologics evaluated	57 16 76	79 24 101
Children		
Gender (F / M)	35 / 22	48 / 31
Age (y), mean ± SD	12.5 ± 3.5	12.3 ± 4.9
Biologics		
Age (y) at first biologic, mean ± SD	8.8 ± 2.3	9.0 ± 0.6
Number de lines of biologics (before 12 years):		
1 line	45	54
2 lines	9	9
3 lines	1	1
4 lines or more	2	2
Biologic evaluated:		
Etanercet	21	35
Adalimumab	36	48
Ustekinumab	13	13
Infliximab	2	2
Secukinumab	1	1
Anakinra	2	2

Inclusions until 15 July 2021

(abstract submitted at the JDP)





25 May 2021





Thanks to the PsoProtect, BSPD, and ESPD groups for their collaboration

Total number of cases reported			48	
Countries that have assessed children	France Portugal	Italy Russia	Poland	
Children				
Girls / boys			21 / 77	
Age (mean ± SD)			12.3 ± 3.9 y	
Psoriasis before COVID-19				
Age of onset of psoriasis (mean ± SD)			6.3 ± 4.0y	
Plaque psoriasis			33	
Nail psoriasis			23	
Psoriasis arthritis			2	
COVID-19				
Confirmed / suspected			41 / 7	
N° of COVID-19 / child				
1			46	
2			1	
Symptoms			20 / 40	
Yes / no			30 / 18	
Hospitalization / oxygen therapy			0/0	
Since COVID-19 onset, the psoriasis has				
Improved			0	
Worsened, with same psoriasis pho	enotype		5	
Worsened, phenotype changed (gu	uttate)		0	
Remained same			36	
Psoriasis de novo			1	
No information			6	
Systemic medication for province at time	o of ancet of COVID	10		
Systemic medication for psoriasis at time Phototherapy 4		19	Ustekinumab	7
Methotrexate 4		3	Risankizumab	1
Acitretin 2		4	Mannizuman	1

You can include children with psoriasis and COVID-19 on:

 $https://docs.google.com/forms/d/e/1FAIpQLSeWcMLUXAfncx4ky8CEUILWa7veJmHb0FthGKuudaQD\\ wbCfNQ/viewform?vc=0\&c=0\&w=1\&flr=0$

Website: https://www.sfdermato.org/site/chi-psocov.html